Zydus Lifesciences Limited

NSE:ZYDUSLIFE.NS

970.35 (INR) • At close November 8, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

202320222021202020192018201720162015201420132012201120102009200820072006200520042003
Revenue 190,215168,778148,276148,215138,121127,484115,99394,29598,37686,51372,24063,57750,90044,64736,86828,62422,66017,85514,45312,43011,962
Cost of Revenue 62,28263,10158,18954,80051,49449,49943,42936,36234,59833,09728,21124,08320,55514,75411,7849,5667,9036,3725,6884,8405,007
Gross Profit 127,933105,67790,08793,41586,62777,98572,56457,93363,77853,41644,02939,49430,34529,89325,08419,05814,75711,4838,7657,5906,955
Gross Profit Ratio 0.6730.6260.6080.630.6270.6120.6260.6140.6480.6170.6090.6210.5960.670.680.6660.6510.6430.6060.6110.581
Reseach & Development Expenses 13,0961,3581,1461,1848971,0791,6891,4421,3881,09057482302,5021,6601,5641,3361,344797736615
General & Administrative Expenses 24,8705,8294,2814,7215,4393,3962,7462,4562,3191,7691,7921,396018,78415,3381,5291,396926495684703
Selling & Marketing Expenses 10,81715,57213,73313,88213,34210,35410,1458,29710,2039,6039,0247,8910005,5424,0933,0122,2521,8131,450
SG&A 35,68721,40118,01418,60318,78113,75012,89110,75312,52211,37210,8169,287018,78415,3387,0715,4893,9382,7472,4972,153
Other Expenses 2,8411,86631518481468013192282424,316-517-465,2794,2943,2392,1232,4792,336
Operating Expenses 82,54177,14965,32067,15266,05954,75649,56242,57342,93138,52733,92429,98124,31620,76918,17813,91411,1198,5215,6675,7125,104
Operating Income 49,04328,52824,74127,35621,01823,92623,00215,36020,84714,88910,1059,5136,0299,1246,9065,1443,6382,9623,0981,8781,851
Operating Income Ratio 0.2580.1690.1670.1850.1520.1880.1980.1630.2120.1720.140.150.1180.2040.1870.180.1610.1660.2140.1510.155
Total Other Income Expenses Net -954-1,6854,102-2,890-5,776364306759390-434-683-1,4261,913-699-867-1,446-404-223-1,330-507-336
Income Before Tax 48,08925,89728,38122,84814,95423,82123,30816,11921,23714,4559,4228,0877,9428,4256,0393,6983,2342,7391,7681,3711,515
Income Before Tax Ratio 0.2530.1530.1910.1540.1080.1870.2010.1710.2160.1670.130.1270.1560.1890.1640.1290.1430.1530.1220.110.127
Income Tax Expense 9,7755,8785,1171,4723,1985,3035,6441,2895,7112,5941,0601,1881,1301,064741666613324243192213
Net Income 38,59519,60344,87321,33611,76618,48817,75814,87715,22611,4858,0366,5356,5267,1105,0513,0312,5762,3381,5241,2151,331
Net Income Ratio 0.2030.1160.3030.1440.0850.1450.1530.1580.1550.1330.1110.1030.1280.1590.1370.1060.1140.1310.1050.0980.111
EPS 37.919.317.6520.8411.4918.0617.3514.5319.1911.247.856.386.376.953.293.22.732.48161.732.552.83
EPS Diluted 37.919.317.6520.8411.4918.0617.3514.5319.1911.247.856.386.376.953.293.22.732.48161.732.552.83
EBITDA 56,68440,46534,28233,99527,82530,45629,27019,88624,61818,02912,80911,2027,60810,3938,2456,2624,6073,7852,9132,4572,562
EBITDA Ratio 0.2980.240.2310.2290.2010.2390.2520.2110.250.2080.1770.1760.1490.2330.2240.2190.2030.2120.2020.1980.214